| 1. |
- Bortz, Robert H., et al.
(författare)
-
Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
- 2021
-
Ingår i: mSphere. - : American Society for Microbiology. - 2379-5042. ; 6:2
-
Tidskriftsartikel (refereegranskat)abstract
- The coronavirus disease 2019 (COVID-19) global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to place an immense burden on societies and health care systems. A key component of COVID-19 control efforts is serological testing to determine the community prevalence of SARS-CoV-2 exposure and quantify individual immune responses to prior SARS-CoV-2 infection or vaccination. Here, we describe a laboratory-developed antibody test that uses readily available research-grade reagents to detect SARS-CoV-2 exposure in patient blood samples with high sensitivity and specificity. We further show that this sensitive test affords the estimation of viral spike-specific IgG titers from a single sample measurement, thereby providing a simple and scalable method to measure the strength of an individual's immune response. The accuracy, adaptability, and cost-effectiveness of this test make it an excellent option for clinical deployment in the ongoing COVID-19 pandemic.IMPORTANCE Serological surveillance has become an important public health tool during the COVID-19 pandemic. Detection of protective antibodies and seroconversion after SARS-CoV-2 infection or vaccination can help guide patient care plans and public health policies. Serology tests can detect antibodies against past infections; consequently, they can help overcome the shortcomings of molecular tests, which can detect only active infections. This is important, especially when considering that many COVID-19 patients are asymptomatic. In this study, we describe an enzyme-linked immunosorbent assay (ELISA)-based qualitative and quantitative serology test developed to measure IgG and IgA antibodies against the SARS-CoV-2 spike glycoprotein. The test can be deployed using commonly available laboratory reagents and equipment and displays high specificity and sensitivity. Furthermore, we demonstrate that IgG titers in patient samples can be estimated from a single measurement, enabling the assay's use in high-throughput clinical environments.
|
|
| 2. |
|
|
| 3. |
- Hammarén, Rickard, 1989-, et al.
(författare)
-
Eurasian back-migration into Northeast Africa was a complex and multifaceted process
- 2023
-
Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 18:11
-
Tidskriftsartikel (refereegranskat)abstract
- Recent studies have identified Northeast Africa as an important area for human movements during the Holocene. Eurasian populations have moved back into Northeastern Africa and contributed to the genetic composition of its people. By gathering the largest reference dataset to date of Northeast, North, and East African as well as Middle Eastern populations, we give new depth to our knowledge of Northeast African demographic history. By employing local ancestry methods, we isolated the Non-African parts of modern-day Northeast African genomes and identified the best putative source populations. Egyptians and Sudanese Copts bore most similarities to Levantine populations whilst other populations in the region generally had predominantly genetic contributions from the Arabian peninsula rather than Levantine populations for their Non-African genetic component. We also date admixture events and investigated which factors influenced the date of admixture and find that major linguistic families were associated with the date of Eurasian admixture. Taken as a whole we detect complex patterns of admixture and diverse origins of Eurasian admixture in Northeast African populations of today.
|
|
| 4. |
- Lewin, Harris A., et al.
(författare)
-
The Earth BioGenome Project 2020 : Starting the clock
- 2022
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences (PNAS). - 0027-8424 .- 1091-6490. ; 119:4
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
- Montagna, Paolo, et al.
(författare)
-
Dissolved neodymium isotopes in the Mediterranean Sea
- 2022
-
Ingår i: Geochimica et Cosmochimica Acta. - : Elsevier BV. - 0016-7037. ; 322, s. 143-169
-
Tidskriftsartikel (refereegranskat)abstract
- The neodymium isotopic composition (εNd) of seawater is one of the most important geochemical tracers to investigate water mass provenance, which can also serve as a proxy to reconstruct past variations in ocean circulation. Nd isotopes have recently also been used to reconstruct past circulation changes in the Mediterranean Sea on different time scales. However, the modern seawater εNd dataset for the Mediterranean Sea, which these reconstructions are based on, is limited and up to now only 160 isotopic measurements are available for the entire basin. The lack of present-day data also limits our understanding of the processes controlling the Nd cycle and Nd isotopic distribution in this semi-enclosed basin. Here we present new εNd data from 24 depth profiles covering all Mediterranean sub-basins, which significantly increases the available dataset in the Mediterranean Sea. The main goal of our study is to better characterize the relationship between the dissolved Nd isotope distributions and major water masses in the Mediterranean Sea and to investigate the impact and relative importance of local non-conservative modifications, which include input of riverine particles and waters, aeolian-derived material and exchange with the sediments at continental margins. This comprehensive εNd dataset reveals a clear εNd – salinity correlation and a zonal and depth gradient with εNd systematically increasing from the western to the eastern Mediterranean basin (average εNd = −8.8 ± 0.8 and −6.7 ± 1 for the entire water column, respectively), reflecting the large-scale basin circulation. We have evaluated the conservative εNd behaviour in the Mediterranean Sea and quantified the non-conservative components of the εNd signatures by applying an Optimum Multiparameter (OMP) analysis and results from the Parametric Optimum Multiparameter (POMP) analysis of Jullion et al. (2017). The results of the present study combined with previously published Nd isotope values indicate that dissolved εNd behaves overall conservatively in the open Mediterranean Sea and show that its water masses are clearly distinguishable by their Nd isotope signature. However, misfits between measured and OMP- and POMP-derived εNd values exist in almost all sub-basins, especially in the eastern Levantine Basin and Alboran Sea at intermediate-deep depths, which can be explained by the influence of detrital lithogenic εNd signatures through interaction with highly radiogenic Nile sourced volcanic fractions and unradiogenic sediments, respectively.The radiogenic signature acquired in the eastern Levantine Basin is carried by the Levantine Intermediate Water and transferred conservatively to the entire Mediterranean at intermediate depths. Our measured εNd values and OMP- and POMP-derived results indicate that non-conservative contributions originating from sediment sources are then propagated by water mass circulation (with distinct preformed εNd) along the Mediterranean Sea through advection and conservative mixing. Mediterranean εNd effectively traces the mixing between the different water masses in this semi-enclosed basin and is a suitable water mass tracer.
|
|
| 6. |
- Pipe, Steven W., et al.
(författare)
-
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
- 2023
-
Ingår i: New England Journal of Medicine. - 0028-4793. ; 388:8, s. 706-718
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting against bleeding without burdensome factor IX replacement. Methods: In this open-label, phase 3 study, after a lead-in period (≥6 months) of factor IX prophylaxis, we administered one infusion of adeno-associated virus 5 (AAV5) vector expressing the Padua factor IX variant (etranacogene dezaparvovec; 2×1013 genome copies per kilogram of body weight) to 54 men with hemophilia B (factor IX activity ≤2% of the normal value) regardless of preexisting AAV5 neutralizing antibodies. The primary end point was the annualized bleeding rate, evaluated in a noninferiority analysis comparing the rate during months 7 through 18 after etranacogene dezaparvovec treatment with the rate during the lead-in period. Noninferiority of etranacogene dezaparvovec was defined as an upper limit of the two-sided 95% Wald confidence interval of the annualized bleeding rate ratio that was less than the noninferiority margin of 1.8. Superiority, additional efficacy measures, and safety were also assessed. Results: The annualized bleeding rate decreased from 4.19 (95% confidence interval [CI], 3.22 to 5.45) during the lead-in period to 1.51 (95% CI, 0.81 to 2.82) during months 7 through 18 after treatment, for a rate ratio of 0.36 (95% Wald CI, 0.20 to 0.64; P<0.001), demonstrating noninferiority and superiority of etranacogene dezaparvovec as compared with factor IX prophylaxis. Factor IX activity had increased from baseline by a least-squares mean of 36.2 percentage points (95% CI, 31.4 to 41.0) at 6 months and 34.3 percentage points (95% CI, 29.5 to 39.1) at 18 months after treatment, and usage of factor IX concentrate decreased by a mean of 248,825 IU per year per participant in the post-treatment period (P<0.001 for all three comparisons). Benefits and safety were observed in participants with predose AAV5 neutralizing antibody titers of less than 700. No treatment-related serious adverse events occurred. Conclusions: Etranacogene dezaparvovec gene therapy was superior to prophylactic factor IX with respect to the annualized bleeding rate, and it had a favorable safety profile.
|
|
| 7. |
- Raj, Satish R, et al.
(författare)
-
Postural orthostatic tachycardia syndrome (POTS) : Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting - Part 2
- 2021
-
Ingår i: Autonomic Neuroscience: Basic & Clinical. - : Elsevier BV. - 1872-7484. ; 235
-
Tidskriftsartikel (refereegranskat)abstract
- The National Institutes of Health hosted a workshop in 2019 to build consensus around the current state of understanding of the pathophysiology of postural orthostatic tachycardia syndrome (POTS) and to identify knowledge gaps that must be addressed to enhance clinical care of POTS patients through research. This second (of two) articles summarizes current knowledge gaps, and outlines the clinical and research priorities for POTS. POTS is a complex, multi-system, chronic disorder of the autonomic nervous system characterized by orthostatic intolerance and orthostatic tachycardia without hypotension. Patients often experience a host of other related disabling symptoms. The functional and economic impacts of this disorder are significant. The pathophysiology remains incompletely understood. Beyond the significant gaps in understanding the disorder itself, there is a paucity of evidence to guide treatment which can contribute to suboptimal care for this patient population. The vast majority of physicians have minimal to no familiarity or training in the assessment and management of POTS. Funding for POTS research remains very low relative to the size of the patient population and impact of the syndrome. In addition to efforts to improve awareness and physician education, an investment in research infrastructure including the development of standardized disease-specific evaluation tools and outcome measures is needed to facilitate effective collaborative research. A national POTS research consortium could facilitate well-controlled multidisciplinary clinical research studies and therapeutic trials. These priorities will require a substantial increase in the number of research investigators and the amount of research funding in this area.
|
|
| 8. |
- Vernino, Steven, et al.
(författare)
-
Postural orthostatic tachycardia syndrome (POTS) : State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1
- 2021
-
Ingår i: Autonomic Neuroscience: Basic and Clinical. - : Elsevier BV. - 1566-0702. ; 235
-
Tidskriftsartikel (refereegranskat)abstract
- Postural orthostatic tachycardia syndrome (POTS) is a chronic and often disabling disorder characterized by orthostatic intolerance with excessive heart rate increase without hypotension during upright posture. Patients often experience a constellation of other typical symptoms including fatigue, exercise intolerance and gastrointestinal distress. A typical patient with POTS is a female of child-bearing age, who often first displays symptoms in adolescence. The onset of POTS may be precipitated by immunological stressors such as a viral infection. A variety of pathophysiologies are involved in the abnormal postural tachycardia response; however, the pathophysiology of the syndrome is incompletely understood and undoubtedly multifaceted. Clinicians and researchers focused on POTS convened at the National Institutes of Health in July 2019 to discuss the current state of understanding of the pathophysiology of POTS and to identify priorities for POTS research. This article, the first of two articles summarizing the information discussed at this meeting, summarizes the current understanding of this disorder and best practices for clinical care. The evaluation of a patient with suspected POTS should seek to establish the diagnosis, identify co-morbid conditions, and exclude conditions that could cause or mimic the syndrome. Once diagnosed, management typically begins with patient education and non-pharmacologic treatment options. Various medications are often used to address specific symptoms, but there are currently no FDA-approved medications for the treatment of POTS, and evidence for many of the medications used to treat POTS is not robust.
|
|
